ATA-200
Limb-Girdle Muscular Dystrophy Type R5 (γ-sarcoglycan-related)
Phase 1/2Active
Key Facts
Indication
Limb-Girdle Muscular Dystrophy Type R5 (γ-sarcoglycan-related)
Phase
Phase 1/2
Status
Active
Company
About Atamyo Therapeutics
Atamyo Therapeutics is a clinical-stage biotech developing AAV-based gene therapies for rare limb-girdle muscular dystrophies (LGMDs). The company has advanced its lead programs, ATA-100 for LGMD-R9 and ATA-200 for LGMD-R5, into clinical trials, with ATA-100 completing a dose-finding study and ATA-200 having dosed multiple patients. As a private, pre-revenue spin-off from the renowned research institute Genethon, Atamyo combines deep scientific expertise in muscular dystrophy genetics with a focused pipeline targeting high-unmet-need rare diseases.
View full company profile